Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases.
Cancers (Basel)
; 15(20)2023 Oct 23.
Article
en En
| MEDLINE
| ID: mdl-37894475
ABSTRACT
BACKGROUND:
We compared CT and MRI for staging metastatic colorectal or neuroendocrine liver metastases (CRLMs and NELMs, respectively) to assess their impact on tumor burden.METHODS:
A prospectively maintained database was queried for patients who underwent both imaging modalities within 3 months, with two blinded radiologists (R1 and R2) independently assessing the images for liver lesions. To minimize recall bias, studies were grouped by modality, and were randomized and evaluated separately.RESULTS:
Our query yielded 76 patients (42 CRLMs; 34 NELMs) with low interrater variability (intraclass correlation coefficients CT = 0.941, MRI = 0.975). For CRLMs, there were no significant differences in lesion number or size between CT and MRI. However, in NELMs, Eovist®-enhanced MRI detected more lesions (R1 14.3 vs. 12.1, p = 0.02; R2 14.4 vs. 12.4, p = 0.01) and smaller lesions (R1 5.7 vs. 4.4, p = 0.03; R2 4.8 vs. 2.9, p = 0.02) than CT.CONCLUSIONS:
CT and MRI are equivalent for CRLMs, but for NELMs, MRI outperforms CT in detecting more and smaller lesions, potentially influencing treatment planning and surgery.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Cancers (Basel)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos